Literature DB >> 24475216

Lymph node ratio for postoperative staging of laryngeal squamous cell carcinoma with lymph node metastasis.

Yu-Long Wang1, Duan-Shu Li1, Yu Wang1, Zhuo-Ying Wang1, Qing-Hai Ji1.   

Abstract

BACKGROUND: Lymph node metastasis has a significant impact on laryngeal cancer prognosis. The role of lymph node ratio (LNR, ratio of metastatic to examined nodes) in the staging of laryngeal cancer was not reported. PATIENTS AND METHODS: Records of laryngeal cancer patients with lymph node involvement from Surveillance, Epidemiology, and End Results database (SEER, training set, N = 1963) and Fudan University Shanghai Cancer Center (FDSCC, validating set, N = 27) were analyzed for the prognostic value of LNR. Kaplan-Meier survival estimates, the Log-rank χ² test and Cox proportional hazards model were used for univariate and multivariate analysis. Optimal LNR cutoff points were identified by X-tile.
RESULTS: Optimal LNR cutoff points classified patients into three risk groups R1 (≤0.09), R2 (0.09-0.20) and R3 (>0.20), corresponding to 5-year cause-specific survival and overall survival in SEER patients of 55.1%, 40.2%, 28.8% and 43.1%, 31.5%, 21.8%, 2-year disease free survival and disease specific survival in FDSCC patients of 74.1%, 62.5%, 50.0%, and 67.7%, 43.2%, 25.0%, respectively. R3 stratified more high risk patients than N3 with the same survival rate, and R classification clearly separated N2 patients to 3 risk groups and N1 patients to 2 risk groups (R1-2 and R3).
CONCLUSIONS: R classification is a significant prognostic factor of laryngeal cancer and should be used as a complementary staging system of N classification.

Entities:  

Mesh:

Year:  2014        PMID: 24475216      PMCID: PMC3903600          DOI: 10.1371/journal.pone.0087037

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

As with other cancers of the head and neck, lymph node (LN) involvement decreases survival rates of laryngeal cancer by approximately 50%. [1] The treatment choice of laryngeal cancer depends on functional outcome, the patient’s wishes, reliability of follow-up, and general medical condition. For early-stage glottic or supraglottic cancers, surgery (partial laryngectomy through either endoscopic or open approaches) and radiotherapy seem to be equally effective. [1], [2], [3] For patients with T4a tumors, the standard approach is a total laryngectomy with ipsilateral thyroidectomy and neck dissection. [1] For managing other locally advanced, resectable glottic and supraglottic cancers, the NCCN guidelines recommended concurrent chemoradiation, surgery or induction chemotherapy as the primary care for individual choice. [1]. Postoperative radiation with or without concurrent chemotherapy were recommended by NCCN for patients with adverse features which included extracapsular nodal spread, positive margin, pT4 primary, N2 or N3 nodal disease, perineural invasion and vasular embolism. [1] Over the past 3 decades, more attention has been paid to the identification of factors that might help the surgeon to assess the precise risk of failure and benefit from more intensified therapy in individual patients. The lymph node ratio (LNR) was found to improve prognostic information in breast cancer, gastric cancer, colorectal cancer, melanoma and others. [4], [5], [6], [7] Although the prevalence of overall metastasis and occult metastasis of lymph nodes were found for 40%–75% and 26%–36% of laryngeal cancer patients, there was still no report about LNR on the survival of laryngeal cancer. [8], [9], [10]. To discuss the role of LNR for the postoperative staging of laryngeal cancer, the SEER (Surveillance, Epidemiology and End Results)-registered laryngeal cancer patients with lymph node metastasis were analyzed and the cutoff points for the LNR in defining patients as high, medium or low risk groups were also identified in current study.

Patients and Methods

Patients

The SEER laryngeal cancer dataset was extracted from SEER database (SEER*Stat 7.0.5). [11] Cancers were limited to the larynx, which were defined as the glottis (C32.0, vocal cord), supraglottis (C32.1, false cord, posterior surface of epiglottis, aryepiglottic fold), subglottis (C32.2), laryngeal cartilage (C32.3), overlapping lesion of larynx (C32.8) and larynx, NOS (C32.9). Histology was limited to squamous cell carcinoma (histology recode - broad groupings 8050–8090). Only laryngeal carcinomas as a single primary tumor or the first of two or more primary tumors were included. The LNR was calculated as the number of positive lymph nodes divided by the number of lymph nodes examined. The cases with dis-concordant N classification information and the number of positive regional lymph nodes recorded in SEER database were rejected. Because the aim of current study was to identify the role of LNR staging for laryngeal cancer, the cases with unclassified T classification, M classification, grade and other variables were also enrolled in the analysis set and were defined as Tx, Mx and unknown group to avoid losing information and select bias. Finally, a total of 4183 cases of laryngeal carcinoma were collected as the analysis set, and among them 1963 cases had pathological lymph node involvement (pN+). The FDSCC (Fudan Univesity Shanghai Cancer Center) laryngeal cancer dataset was built prospectively and recorded the layngeal cancer patients treated at Cancer Hospital, Fudan University, Shanghai, China from January, 2003 to January 2012. To avoid the bias caused by pre-operative radiotherapy and/or chemotherapy, and occult LNs metastasis, only patients primarily operated with neck dissection were enrolled in current research. The Pathologic reviews showed that 27 patients were pN+ which included 5 pN1 and 22 pN2 according to AJCC staging system. The 2-year disease specific survival (DSS, laryngeal cancer specific) and disease free survival (DFS, no local recurrence and distant metastasis) for pN+ laryngeal cancer patients were 66.3% and 51.0%, respectively.

Ethics Statement

For SEER cases, this study was based on public use de-identified data from the U.S. SEER database and did not include interaction with human subjects or use personal identifying information. The study did not require informed consent from the SEER registried cases and the authors obtained Limited-Use Data Agreements from SEER. For FDSCC patients, written informed consent were obtained. The study was approved by the Review Board of Fudan Univesity Shanghai Cancer Center, Shanghai, China.

Statistical Analysis

Firstly, we evaluated the prognostic value of LNR as a continuous variable, adjusting for other covariates associated with survival of 1963 SEER pN+ laryngeal cancer cases. Furtherly, we proceeded to determine the most appropriate cutoff points for categorizing LNR as high, medium, and low risk groups. Two pairs of cutoff points were identified using different methods and compared with LNR as a continuous variable to identify the optimal cutoff points. The first pair of cutoff points were identified by tertiles to split the patients into equal sized groups. [12], [13] The second pair cutoff points were calculated by X-tile using the minimum P values from log-rank χ2 statistics. [14] Finally, the prognostic significance of LNR staging was validated in FDSCC patients. The survival rate and curves was calculated using the Kaplan–Meier method. Statistical comparisons of different factors with mortality were made with the Log-rank χ2 test. In multivariate analysis, forward stepwise regression analysis was carried out with a Cox proportional hazards model. Harrell’s concordance index (C-index) and AIC (Akaike information criterion) value related to the Cox regression model were analyzed to compare the predictive ability of the staging system. A smaller AIC value and a higher C-index value indicated a more desirable model for predicting outcome. A P value of 0.05 was considered statistically significant. All statistical analyses were carried out using SPSS software version 17.0 (SPSS Inc., Chicago, IL) and R2.14.0 software with packages (MASS and Survival).

Results

LNR is a Prognostic Factor of Laryngeal Cancer Survival

The clinical characteristics, 5-year cause specific survival (CSS) and overall survival (OS) estimates, and Log-rank χ2 test of univariate variables of the 1963 SEER patients with pN+ laryngeal cancer were shown in Table 1. Using multivariate Cox regression analysis, we found that race, radiation sequence, T classification, N classification, M classification, continuous LNR and age were all independent variables for predicting survival (Table 2).
Table 1

Clinicopathological characteristics, cause specific survival (CSS) and overall survival (OS) of SEER laryngeal cancer cases with pathological lymph node involvement.

Categorical variablesNo. of patients5-year CSS5-year OS
(n = 1963)Rate (%)Log-rank χ2 P valueRate (%)Log-rank χ2 P value
Race3.9650.1385.2890.071
White1480 (75.4%)43.733.9
Black397 (20.2%)38.829.7
Other86 (4.4%)48.140.9
Gender2.7950.0951.5450.214
Male1526 (77.7%)42.132.4
Female437 (22.3%)45.936.8
Year of diagnosis0.3900.8230.2280.892
1988–1994429 (21.9%)43.333.1
1995–2001637 (32.5%)42.434.0
2002–2008897 (45.7%)43.432.3
Primary site15.2710.00915.8030.007
Glottis327 (16.7%)40.932.5
Supraglottis1285 (65.5%)44.834.7
Subglottis36 (1.8%)032.1
Laryngeal cartilage11 (0.6%)32.724.2
Overlapping lesion133 (6.8%)41.029.6
Larynx, NOS171 (8.7%)36.028.7
Histological grade17.0370.00221.628<0.001
I89 (4.5%)44.434.3
II937 (47.7%)45.336.5
III783 (39.9%)42.231.6
IV20 (1.0%)46.120.0
Unknown134 (6.8%)27.922.3
Radiation sequence33.328<0.00156.831<0.001
No radiation504 (25.7%)35.423.7
Pre-operative72 (3.7%)38.328.9
Post-operative1363 (69.4%)45.937.2
Other24 (1.2%)38.327.3
Cancer directed surgery26.251<0.00127.370<0.001
Yes1761 (89.7%)44.534.8
Other202 (10.3%)26.118.6
T staging59.303<0.00154.620<0.001
T1182 (9.3%)57.746.2
T2526 (26.8%)48.536.1
T3295 (15.0%)42.134.7
T4a809 (41.2%)39.331.2
T4b55 (2.8%)29.620.3
Tx96 (4.9%)24.517.6
N staging61.415<0.00147.574<0.001
N1546 (27.8%)59.747.3
N21313 (66.9%)37.128.8
N3104 (5.3%)31.920.6
M staging55.169<0.00145.658<0.001
M01845 (94.0%)44.134.3
M189 (4.5%)19.215.4
Mx29 (1.5%)40.829.4
Continuous variablesMedian (range)
Age60 years (17–91)
No. of LN examined28(1–90)
No. of positive LNs2(1–90)
Lymph node ratio0.11(0.01–1.00)
Table 2

Multivariate analysis of the lymph node ratio (LNR) and covariates associated with survival of laryngeal cancer cases with lymph node metastasis.

VariablesCause specific survivalOverall survival
HR(95% CI) P valueHR(95% CI) P value
Race (White as reference)
Black1.212(1.041–1.412)0.0131.238(1.084–1.413)0.001
Other0.920(0.674–1.252)0.5920.858(0.652–1.123)0.261
Radiation sequence (no radiation as reference)
Pre-operative0.846(0.606–1.182)0.3280.839(0.627–1.123)0.238
Post-operative0.694(0.599–0.805)<0.0010.654(0.577–0.743)<0.001
Other0.976(0.556–1.714)0.9320.952(0.574–1.579)0.848
T classification (T1 as reference)
T21.308(1.013–1.689)0.0401.277(1.033–1.577)0.024
T31.740(1.316–2.301)<0.0011.540(1.216–1.951)<0.001
T4a1.856(1.450–2.375)<0.0011.630(1.327–2.002)<0.001
T4b2.365(1.574–3.552)<0.0012.157(1.526–3.048)<0.001
Tx1.963(1.285–3.001)0.0021.725(1.186–2.511)0.004
N classification (N1 as reference)
N21.948(1.668–2.274)<0.0011.642(1.445–1.865)<0.001
N31.806(1.358–2.402)<0.0011.668(1.309–2.127)<0.001
M classification (M0 as reference)
M11.700(1.194–2.420)0.0031.579(1.137–2.195)0.006
MX0.722(0.386–1.349)0.3070.864(0.510–1.466)0.588
LNR as continuous variable2.299(1.905–2.775)<0.0011.810(1.532–2.138)<0.001
Age1.013(1.006–1.019)<0.0011.020(1.014–1.025)<0.001

Cutoff Points Identification of LNR

To stratify the patients with lymph node metastasis as high, medium and low risk groups associated with CSS, the upper and lower tertiles of continuous LNR that corresponded to 0.06 and 0.23 were defined as the first pair of cutoff points. The X-tile, which can control the inflated type I error problem and minimize the loss of information due to multiple testing through cross-validation, identified 0.09/0.20 as the second pair of cutoff points. [6], [14] The SEER cases with lymph node metastasis were stratified as high, medium and low risk groups according to the two pairs of cutoff points identified above. The case numbers, the 5-year CSS and 5-year OS of the different risk groups were summarized in Table 3. To compare the predictive ability of the categorical LNR and the continuous LNR, the C-index and AIC value of the Cox regression model (Table 2) with substitution of the continuous LNR with the categorical LNR were calculated. As listed in Table 3, the models of categorical LNRs defined by cutoff points 0.09/0.20 showed superior predictive ability to that of the continuous LNR and another categorical LNR, with the lowest AIC value and highest C-index value associated with the Cox regression model. The SEER laryngeal cancer patients with lymph node metastasis were classified as R1 (LNR ≤0.09), R2 (LNR 0.10–0.20) and R3 (LNR >0.20) three risk groups (R classification).
Table 3

Univariate and multivariate analysis of the categorical and continuous LNR with cause-specific survival (CSS) and overall survival (OS) of SEER laryngeal cancer patients with lymph node metastasis.

LNRclassificationCaseNo.5-yearCSS(%)Log-rankχ2 (P )Multivariate analysis of CSS 5-yearOS(%)Log-rankχ2 (P )Multivariate analysis of OS
HR (95% CI)C-indexAICHR (95% CIs)C-indexAIC
Continuous LNR2.299(1.905–2.775)0.65814037.851.810(1.532–2.138)0.64218430.78
Cutpoints 0.06/0.23109.1970.65814042.8387.7290.64218432.54
R1: 0–0.0663756.3(<0.001)Reference43.9(<0.001)Reference
R2: 0.06–0.2373742.41.270(1.074–1.502)33.41.233(1.070–1.421)
R3: >0.2358929.41.928(1.635–2.273)22.21.624(1.409–1.871)
Cutpoints 0.09/0.20125.2280.66114027.1494.6730.64518424.27
R1: 0–0.0986055.1(<0.001)Reference43.1(<0.001)Reference
R2: 0.09–0.2045840.21.421(1.202–1.680)31.51.308(1.133–1.509)
R3: >0.2064528.81.962(1.695–2.271)21.81.607(1.416–1.825)

The multivariate analysis was adjusted using the same Cox regression model at Table 2.

The multivariate analysis was adjusted using the same Cox regression model at Table 2.

Selecting High Risk Patients by R classification

N classification was widely used for postoperative staging of lymph node of laryngeal cancer, while the cause specific survival curves of N3 crossed with N2 after 150 months follow-up (Figure 1A). N1, N2 and N3 accounted for 27.8%, 66.9% and 5.3% of all pN+ patients (Table 1). Compared with pN classification, the survival curves of individual R classification separated clearly even after 20 years follow-up (Figure 1C and 1D). The R classification also showed homogenous patients grouping which stratified the patients to 43.8% (R1), 23.3% (R2) and 32.9% (R3) of all pN+ patients (Table 3). The 5 and 10-year CSS and OS of N3 patients were and 31.9%, 22.7% and 20.6%, 11.1%, individually. The 5 and 10-year CSS and OS of R3 patients were and 28.8%, 19.8% and 21.8%, 12.0%, respectively. R3 stratified more high risk patients than N3 with the same survival rate.
Figure 1

Kaplan–Meier survival estimates according to pN classification and R classification of SEER laryngeal cancer patients with lymph node metastasis: cause-specific survival (A) and overall survival (B) of the SEER set with different pN classification; cause-specific survival (C) and overall survival (D) of the SEER set with different R classification.

R classification Stratify Individual N Patients to Different Risk Groups

To further analyze the role of R classification for stratify patients to different risk groups, the R classification were defined for patients with individual N classification. For pN1 patients, the 5-year CSS and OS of R1 (N = 361), R2 (N = 40), R3 (N = 145) groups were 65.3%, 67.0%, 43.5% (Log-rank χ2 32.117, P<0.001) and 52.7%, 51.7%, 33.0% (Log-rank χ2 27.654, P<0.001), respectively (Figure 2A and 2B). For pN2 patients, the 5-year CSS and OS of R1 (N = 468), R2 (N = 400), R3 (N = 445) groups were 48.5%, 37.1%, 25.1% (Log-rank χ2 63.523, P<0.001) and 37.6%, 29.6%, 18.9% (Log-rank χ2 45.328, P<0.001), respectively (Figure 2C and 2D). No significant differences of CSS (Log-rank χ2 5.493, P = 0.064) and OS (Log-rank χ2 2.713, P = 0.258) were observed for individual R classification group of pN3 patients (N = 104). R classification clearly separated N2 patients to 3 risk groups and N1 patients to 2 risk groups (R1–2 and R3). The survival of R1 patients of N2 classification is better than the survival of R3 patients of N1 classification. All these results supported that R classification can stratify the patients to different risk groups and complement N classification.
Figure 2

Kaplan–Meier survival estimates of different R classification patients of individual N classification.

The cause-specific survival (A) and overall survival (B) of individual R classification for pN1 patients; cause-specific survival (C) and overall survival (D) of individual R classification for pN2 patients.

Kaplan–Meier survival estimates of different R classification patients of individual N classification.

The cause-specific survival (A) and overall survival (B) of individual R classification for pN1 patients; cause-specific survival (C) and overall survival (D) of individual R classification for pN2 patients.

Validation of R Classification in FDSCC Patients

To validate R classification in the FDSCC patient set, 27 pN+ cases were analyzed and the median number of LNs examined, positive LNs and LNR were 38 (range, 8–123), 2 (range, 1–28) and 0.09 (range, 0.01–0.70), respectively. The 2-year DSS and DFS of R1 (N = 13), R2 (N = 10), R3 (N = 4) patients were 74.1%, 62.5%, 50.0%, and 67.7%, 43.2%, 25.0%, respectively. The 2-year DSS and DFS of N1 (N = 5) and N2 (N = 22) patients were 50.0%, 69.5% and 50% and 47.6%, respectively. Although no statistical significance were found for survival difference of individual R classification and N classification due to less patients number, the R classification stratify patients to 3 risk groups clearly.

Discussion

When surgery was selected as the primary management of laryngeal cancer, more attention should be paid to identify factors that might help the surgeon to assess the precise risk of failure. The main prognosticators included T classification, quality of surgical resection, positive margins, two or more positive lymph nodes, largest node >3 centimeters in diameter, perineural invasion, and in some studies, age and gender. [15], [16] In 2004, level I evidence was established for the postoperative chemoradiotherapy treatment of patients with selected high risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in EROTC and RTOG. Extracapsular extension and/or microscopically involved surgical margins were the only risk factors for which the impact of chemotherapy enhanced radiation therapy was significant in both trials. [17] Our current results identified that lymph node ratio is as independent risk factors for the postoperative staging of laryngeal cancer. The R classification defined by the cutoff points 0.09/0.20 can clearly stratify patients to different risk groups and complement the pN classification. The R classification should be incorporated into the risk factors mentioned above to stratify patients and assess the treatment benefits. In this exciting and chaotic period in which new chemotherapy agents, new paradigms of treatment, new surgical and radiation technology, and new prognostic factors are rapidly becoming available, a multidisciplinary and collaborative approach for each patient at the start of decision making and planning is a necessity and the absolute standard of medical treatment for excellent patient care. [18]. The significant decrease in the number of laryngeal cancer surgical cases and changing use of new drugs and radiation techniques in the chemoradiation era prevent a clear and accurate analysis of risks of postoperative failure based on single institution’s experience. SEER data are abstracted prospectively from registries comprising 26% of U.S. population, which is considered representative of the entire population, and the selection biases, recall biases, treatment fads, influence of loss to follow-up and other oversights associated with single institution’s research were minimized. [11], [19] Current studies use the largest series (SEER) of operated pN+ laryngeal cancer cases to analysis the role of R classification for staging of laryngeal caner and validate the R classification in an independent dataset (FDSCC). The complementary data collection system and the cross-validation of SEER and FDSCC dataset reinforce the conclusion. While limitations still exist for current research, such as the inter-institution differences in patient management, unrecorded details of pathologic reports and medical management covariates of SEER dataset, the less patient number of FDSCC dataset. Integrating R classification with other risk factors to analysis the pooled data of inter-institutional clinical trials will achieve a definitive result of the postoperative staging of laryngeal cancer. In conclusion, we clearly identify that lymph node ratio was an independent prognostic factor of laryngeal cancer and R classification (LNR 0–0.09, LNR 0.09–0.20 and LNR >0.20)defines laryngeal cancer mortality adequately. R staging is a complementary staging system for N classification. R staging based stratification of patients for postoperative therapy and clinical trials deserved for further research.
  18 in total

Review 1.  Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer.

Authors:  M R Posner
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 2.  Head and neck cancers.

Authors:  David G Pfister; Kie-Kian Ang; David M Brizel; Barbara A Burtness; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Merrill S Kies; William M Lydiatt; Ellie Maghami; Renato Martins; Thomas McCaffrey; Bharat B Mittal; Harlan A Pinto; John A Ridge; Sandeep Samant; Giuseppe Sanguineti; David E Schuller; Jatin P Shah; Sharon Spencer; Andy Trotti; Randal S Weber; Gregory T Wolf; Frank Worden
Journal:  J Natl Compr Canc Netw       Date:  2011-06-01       Impact factor: 11.908

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection--results of a single-institution study of 1343 Chinese patients.

Authors:  W Wang; D Z Xu; Y F Li; Y X Guan; X W Sun; Y B Chen; R Kesari; C Y Huang; W Li; Y Q Zhan; Z W Zhou
Journal:  Ann Oncol       Date:  2011-02-10       Impact factor: 32.976

5.  Lymph node ratio provides prognostic information in addition to american joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized.

Authors:  Andrew J Spillane; Bernard L H Cheung; Julie Winstanley; John F Thompson
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

6.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

7.  Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer.

Authors:  Vincent Vinh-Hung; Sue A Joseph; Nadege Coutty; Bevan Hong Ly; Georges Vlastos; Nam Phong Nguyen
Journal:  Oncologist       Date:  2010-10-07

8.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

Review 9.  Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review.

Authors:  W Ceelen; Y Van Nieuwenhove; P Pattyn
Journal:  Ann Surg Oncol       Date:  2010-06-18       Impact factor: 5.344

10.  Lymph node ratio as an alternative to pN staging in node-positive breast cancer.

Authors:  Vincent Vinh-Hung; Helena M Verkooijen; Gerald Fioretta; Isabelle Neyroud-Caspar; Elisabetta Rapiti; Georges Vlastos; Carole Deglise; Massimo Usel; Jean-Michel Lutz; Christine Bouchardy
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

View more
  9 in total

1.  Lymph node yield and lymph node density for elective level II-IV neck dissections in laryngeal squamous cell carcinoma patients.

Authors:  Melih Cayonu; Evrim Unsal Tuna; Aydın Acar; Ayse Secil Kayalı Dinc; Muammer Melih Sahin; Suleyman Boynuegri; Adil Eryilmaz
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-17       Impact factor: 2.503

2.  A critical evaluation of lymph node ratio in head and neck cancer.

Authors:  M de Ridder; C C M Marres; L E Smeele; M W M van den Brekel; M Hauptmann; A J M Balm; M L F van Velthuysen
Journal:  Virchows Arch       Date:  2016-09-18       Impact factor: 4.064

3.  Matched-pair analysis of survival in patients with poorly differentiated versus well-differentiated glottic squamous cell carcinoma.

Authors:  Ping Chen; Wenbin Yu; Junwei Huang; Hongbo Xu; Guojun Li; Xiaohong Chen; Zhigang Huang
Journal:  Oncotarget       Date:  2017-02-28

4.  The Prognostic Significance of Lymph Node Ratio and Log Odds Ratio in Laryngeal Squamous Cell Carcinoma.

Authors:  Xinrui Zhang; Feng Yu; Zheng Zhao; Junhao Mai; Yibo Zhou; Guojie Tan; Xuekui Liu
Journal:  OTO Open       Date:  2018-09-27

5.  Prognostic value of lymph node ratio in laryngeal and hypopharyngeal squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  Arikin Abdeyrim; Shizhi He; Yang Zhang; Gulbostan Mamtali; Aibadla Asla; Mirkamil Yusup; Jiang Liu
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-05-29

6.  PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.

Authors:  Nan Wang; Honghong Yan; Di Wu; Zheng Zhao; Xiaoqi Chen; Qian Long; Changlin Zhang; Xiaohao Wang; Wuguo Deng; Xuekui Liu
Journal:  Cell Death Dis       Date:  2020-10-15       Impact factor: 8.469

7.  Long non-coding RNA profiling in laryngeal squamous cell carcinoma and its clinical significance: potential biomarkers for LSCC.

Authors:  Zhisen Shen; Qun Li; Hongxia Deng; Dakai Lu; Haojun Song; Junming Guo
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

8.  The prognostic value of negative lymph node count for patients with cervical cancer after radical surgery.

Authors:  Hao Lu; Rong Guo; Haotian Yang; Haolu Wang; Xiaowen Liang; Zhiqian Hu; Xinxing Li
Journal:  Oncotarget       Date:  2017-12-21

9.  Development of comprehensive nomograms for evaluating overall and cancer-specific survival of laryngeal squamous cell carcinoma patients treated with neck dissection.

Authors:  Xiao Shi; Wei-Ping Hu; Qing-Hai Ji
Journal:  Oncotarget       Date:  2017-05-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.